Key vendors to increase their sales through the development of new diagnostic platform
Technavio, a company that develops over 2000 pieces of research every year and covers more than 500 technologies across 80 countries, has announced the top five leading vendors for the global cervical cancer diagnostic testing market in their latest research report. This report also lists 24 other prominent vendors who are expected to contribute to this market’s growth between 2016-2020.
To identify the top vendors, Technavio’s market research analysts have taken into account the revenue generated from the sales of cervical cancer testing products used to perform cervical cancer screening.
- Pap smear test: This test detects potentially precancerous and cancerous cells in the endocervical canal.
- HPV testing: This is a very sensitive test conducted along with the Pap smear test using some of the same liquid-based cell samples.
This Technavio report, under in-vitro diagnostics vertical, is based on the synthesis, analysis, and interpretation of information about the global cervical cancer diagnostic testing market collected from specialized sources. The analysts have derived insights using a mix of primary and secondary research with an aim to provide a holistic picture of the market.
Click here to request a free sample of this report
Competitive vendor landscape
The advances in technology and product upgradation is expected to intensify the competition among the various players in the market. The cervical cancer diagnostic testing market consists of various large, medium, and small-sized companies that control the level of competition in the market. The vendors in the market are competing on the basis of pricing, product sensitivity, product differentiation, high investments, and technology upgradation. The primarily end-users of this market are hospitals, clinical diagnostic laboratories, and physician office laboratories. The companies in the market are using improved predictive markers and diagnostic methods in a combination of various techniques to achieve accurate results and increase profitability. The introduction of automated cervical cancer screening will help the manufacturers sustain the fierce competition in the market.
“The vendors in the market are investing in the research and development of new technologies in order to improve the detection of cervical cancer. Some of the advanced technology launched in the market are based on thin-layer preparations, computer-assisted screening methods, and new generation HPV testing methods. These new test series help to enhance the quality and adequacy of the Pap smear test and its interpretation. The vendors are designing tests to decrease the number of unsatisfactory smears yielding ambiguous results,” says Barath Palada, a lead analyst at Technavio for research on in-vitro diagnostics.
Top five vendors in the cervical cancer diagnostic testing market space
Abbott Molecular
The company offers point-of-care devices to various departments including hospitals, ambulatory care centers, laboratories, long-term care centers, government agencies, emergency departments, critical care centers, and other departments. Recently, the company launched Alinity diagnostic systems.
Key products: m2000 RealTime System and Abbott RealTime High Risk HPV.
Becton, Dickinson & Company (BD)
This medical technology company manufactures and sells a broad range of medical supplies, laboratory equipment, devices, and diagnostic products. In recent times, the company submitted a pre-market approval application to FDA for the BD Onclarity HPV Assay.
Key products: BD SurePath, BD Onclarity HPV assay, BD Viper LT System, BD Totalys MultiProcessor, and BD Totalys SlidePrep.
Hologic
Hologic develops, manufactures, and supplies medical imaging systems, diagnostics products, and surgical products and it focuses on the diagnostics, breast health, GYN (gynecology) surgical, and skeletal health. Recently, it launched MyoSure REACH device for physicians to reach upper third of uterine cavity.
Key products: ThinPrep Pap test, ThinPrep Cervista HPV test, Aptima HPV assay, Aptima HPV 16 18/45 genotype assay, and Panther system.
QIAGEN
The company provides sample and assay technologies that are used to isolate RNA, DNA, and proteins from blood and tissue samples that contain biological materials. These technologies are used to amplify, enrich, and provide results for analysis. Recently, the company announced the successful completion of a tender offer for shares in Exiqon.
Key products: digene HC2 HPV DNA Test, digene HC2 Sample Conversion Kit, and careHPV Test.
Quest Diagnostics
Quest Diagnostics offers diagnostic testing services for cardiovascular disease, cancer, neurological disorders and infectious diseases. Recently, the company partnered with Optum to help make the health system work better.
Key products: Cervical Cancer TERC Test, HPV mRNA Genotype Test, and HPV mRNA Test.
Other prominent vendors in this market include Arbor Vita, Autogenomics, bioMérieux, BioVantra, Cancer Genetics, Cepheid, Cervia Diagnostics, Cytoimmun, DAAN Gene, Delphi Bioscience, DiaCarta, Fujirebio, Genera Biosystems, Greiner Bio-One, Guided Therapeutics, GynaeHealth, IncellDx, Micromedic Technologies, Norchip, OncoHealth, OralDNA Labs, Seegene, Solopap International, and Trovagene.
A more detailed analysis is available in the Technavio report, Global Cervical Cancer Diagnostic Testing Market 2016-2020.Technavio also customizes reports by other regions and specific segments upon request.
To read more press releases- click here.
Browse related reports:
- Solid Tumor Testing Market in the US 2016-2020
- Global Cancer Diagnostic Devices Market 2016-2020
- Global Tissue Diagnostics Market 2016-2020
For any assistance or query, please contact our media team at:
media@technavio.com
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com
